VLP Biotech
Private Company
Funding information not available
Overview
VLP Biotech is a private, preclinical-stage biotech firm specializing in vaccine development for infectious diseases using its proprietary recombinant protein platform. The company operates a service-based model for custom antibody production while advancing its own vaccine candidates through early-stage government-funded grants. With a lean structure, it has secured non-dilutive funding from entities like Leidos and the U.S. government's SBIR/STTR programs to fuel its R&D efforts. Its strategy combines contract services with internal pipeline development to address significant unmet medical needs.
Technology Platform
Proprietary vaccine platform for engineering custom recombinant proteins and virus-like particles (VLPs) for antibody production and immunogen design.
Opportunities
Risk Factors
Competitive Landscape
VLP Biotech competes with large vaccine developers (GSK, Pfizer, Merck) and numerous biotechs in malaria, RSV, and MRSA. In RSV, it faces recently approved products from Pfizer, GSK, and others. Its differentiation lies in its proprietary protein engineering platform and focus on specific antigen design, but it must demonstrate superior efficacy or safety to gain market share.